Exercise of Warrants

SalvaRx Group plc

 ("SalvaRx" or the "Company")

Exercise of Warrants

SalvaRx (LON: SALV), a biotechnology company focused on immunotherapy for cancer, announces that the Company has issued and allotted 60,563 ordinary shares of 2.5 pence each in the capital of the Company ("Ordinary Shares") at a price of 35.5 pence per share following an exercise of warrants.

The Company has made an application for the 60,563 new Ordinary Shares to be admitted to trading on AIM ("Admission"). Admission is expected to occur at 8.00 a.m. on 12 October 2018. The 60,563 new Ordinary Shares will rank pari passu with the existing Ordinary Shares.

Total Voting Rights

For the purpose of the Disclosure and Transparency Rules, following Admission, the Company's total issued ordinary share capital will consist of 36,527,182 Ordinary Shares. The Company does not hold any shares in treasury. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Disclosure and Transparency Rules.

Enquiries